Kate Ellmer is an accomplished executive in the field of quality systems and compliance, currently serving as the Executive Director at CRISPR Therapeutics since February 2023. With a robust career at Alexion Pharmaceuticals from September 2014 to February 2023, Kate held multiple key roles including Senior Director of Quality Management System Oversight & Operations, and several director-level positions focusing on patient advocacy, regulatory intelligence, and compliance. Prior experience includes a Clinical Quality Assurance Manager position at Exelixis and roles at JANSSEN Alzheimer Immunotherapy and UCB in drug safety and compliance. Kate began her career as a DEA Compliance Specialist and research assistant. Educational qualifications include a Bachelor of Science in Biology from Arizona State University, a Certificate in Clinical Trials Design and Management from San Francisco State University, and a Master's degree in Public Health from San José State University.
This person is not in any teams
This person is not in any offices